BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1377 related articles for article (PubMed ID: 26727762)

  • 1. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
    Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
    J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
    Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
    Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy.
    Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
    Asian Pac J Allergy Immunol; 2013 Sep; 31(3):233-41. PubMed ID: 24053706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
    Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
    Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis.
    Wang ZX; Shi H
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):407-411. PubMed ID: 28585143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
    Richards JR; Stumpf JL
    Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and cytokine responses to house dust mite sublingual immunotherapy.
    Potter PC; Baker S; Fenemore B; Nurse B
    Ann Allergy Asthma Immunol; 2015 Apr; 114(4):327-34. PubMed ID: 25661658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma.
    Ozdemir C; Yazi D; Gocmen I; Yesil O; Aydogan M; Semic-Jusufagic A; Bahceciler NN; Barlan IB
    Pediatr Allergy Immunol; 2007 Sep; 18(6):508-15. PubMed ID: 17680909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on house dust mite immunotherapy: are more studies needed?
    Nelson HS
    Curr Opin Allergy Clin Immunol; 2014 Dec; 14(6):542-8. PubMed ID: 25115684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Functional IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy Correlates with IgG4 Antibodies and a Decrease of Symptoms in House Dust Mite-Allergic Children.
    Zhao D; Lai X; Tian M; Jiang Y; Zheng Y; Gjesing B; Zhong N; Spangfort MD
    Int Arch Allergy Immunol; 2016; 169(2):113-20. PubMed ID: 27049773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in CD4+CD25+FoxP3+ Regulatory T Cells and Serum Cytokines in Sublingual and Subcutaneous Immunotherapy in Allergic Rhinitis with or without Asthma.
    Xian M; Feng M; Dong Y; Wei N; Su Q; Li J
    Int Arch Allergy Immunol; 2020; 181(1):71-80. PubMed ID: 31722337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases.
    Li P; Li Q; Huang Z; Chen W; Lu Y; Tian M
    Int Forum Allergy Rhinol; 2014 Oct; 4(10):796-801. PubMed ID: 25145986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged effect of allergen sublingual immunotherapy for house dust mites in elderly patients.
    Bozek A; Starczewska-Dymek L; Jarzab J
    Ann Allergy Asthma Immunol; 2017 Jul; 119(1):77-82. PubMed ID: 28668244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of mucosal/systemic antibody response after sublingual immunotherapy in mite-allergic children.
    Queirós MG; Silva DA; Siman IL; Ynoue LH; Araújo NS; Pereira FL; Almeida KC; Miranda JS; Pena JD; Cunha-Junior JP; Taketomi EA
    Pediatr Allergy Immunol; 2013 Dec; 24(8):752-61. PubMed ID: 24299565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.
    Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I
    J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.
    Soyyigit S; Guloglu D; Ikinciogullari A; Secil D; Oztuna D; Mungan D; Misirligil Z; Sin BA
    Ann Allergy Asthma Immunol; 2016 Mar; 116(3):244-251.e2. PubMed ID: 26945497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.